Company Overview and News

0
Alliance Data Systems Corporation (ADS) CEO Ed Heffernan on Q2 2018 Results - Earnings Call Transcript

3h seekingalpha
Alliance Data Systems Corporation (NYSE:ADS) Q2 2018 Results Earnings Conference Call July 19, 2018 8:30 AM ET
VA ADS

0
Alliance Data Systems Corporation 2018 Q2 - Results - Earnings Call Slides

3h seekingalpha
The following slide deck was published by Alliance Data Systems Corporation in conjunction with their 2018 Q2 earnings call.
ADS

2
Alliance Data (ADS) Q2 Earnings Top, Tweaks Revenue View

4h zacks
Alliance Data Systems Corporation’s (ADS - Free Report) operating earnings of $5.01 per share in the second quarter of 2018 surpassed the Zacks Consensus Estimate of $4.59. Also, the bottom line improved 31% year over year on the strength of Card Services and LoyaltyOne segment results.
GLO GTMEY MA GTMEF WEX FIS GLOPP ADS GLOPA

3
Alliance Data (ADS) Q2 Earnings and Revenues Beat Estimates

7h zacks
Have you been eager to see how Alliance Data Systems Corporation (ADS - Free Report) performed in the second quarter in comparison with the market expectations? Let’s quickly scan through the key facts from this OH-based property and casualty insurer’s earnings release this morning. An Earnings Beat Alliance Data reported adjusted earnings per share of $5.01 per share, beating the Zacks Consensus Estimate of $4.
NBRV EIGR ADS NCS

0
Diversified Royalty Corp. Announces Preliminary Q2 2018 Results for Mr. Lube, AIR MILES and Sutton

8h globenewswire
VANCOUVER, British Columbia, July 19, 2018 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX:DIV) (TSX:DIV.DB) (the “Corporation” or “DIV”) is pleased to announce preliminary results for Mr. Lube, AIR MILES® and Sutton for the three months ended June 30, 2018 (“Q2 2018”).
BEVFF DIV ADS TU

0
ADS / Alliance Data Systems Corp. FORM 8-K (Current Report)

9h sec.gov
SECURITIES AND EXCHANGE COMMISSION
ADS

0
17
Should You Buy Alliance Data Systems (ADS) Ahead of Earnings?

2018-07-18 zacks
Investors are always looking for stocks that are poised to beat at earnings season and Alliance Data Systems Corporation (ADS - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Alliance Data Systems is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to earnings beat.
OCUL JAKK FTRPR ADS FTR

7
Will Strong Segments Aid Alliance Data's (ADS) Q2 Earnings?

2018-07-17 zacks
Alliance Data Systems Corporation (ADS - Free Report) is slated to report second-quarter 2018 results on Jul 19, before the market opens. Last reported quarter, the company delivered a positive earnings surprise of 25.20%. Let’s see, how things are shaping up for this announcement. Card Service — accounting for more than 50% of the company’s revenues — will continue to contribute majorly to the company’s overall performance.
V WEX FIS ADS

0
ADS / Alliance Data Systems Corp. FORM 8-K (Current Report)

2018-07-17 sec.gov
SECURITIES AND EXCHANGE COMMISSION
ADS

0
Monday’s Biggest Winners and Losers in the S&P 500

2018-07-16 247wallst
July 16, 2018: The S&P 500 closed flat at 2,798.42. The DJIA closed up 0.2% at 25,063.68. Separately, the Nasdaq was down 0.3% at 7,805.72.
VFC ADS

0
Stocks are mixed as banks move higher and oil prices slump

2018-07-16 nzherald.co.nz
NEW YORK (AP) — U.S. stocks are mixed Monday morning as banks rise along with interest rates but energy companies sink along with the price of oil. Stocks finished at five-month highs last week as investors remained optimistic about the U.S. economy even as they worried about the trade war between the U.S. and China as well as other tensions.
DB NDAQ ADS

0
ADS / Alliance Data Systems Corp. FORM 8-K (Current Report)

2018-07-16 sec.gov
SECURITIES AND EXCHANGE COMMISSION
ADS

0
ADS / Alliance Data Systems Corp. FORM 8-K (Current Report)

2018-07-12 sec.gov
SECURITIES AND EXCHANGE COMMISSION
ADS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ADS / Alliance Data Systems Corp. on message board site Silicon Investor.

Good Reads Deadheads
Autodesk (ADSK), sales now increasing! Bid /Ask Spreads - Market Manipulation
Railroad industry: Freight railroads/rail supply companies ADSL IS DEAD
Infrastructure Industry: Toll-roads, Ports, Airports ADST new undiscovered gem
ADSX Iron condors and other credit spreads
CUSIP: 018581108